an20131024-8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  October 22, 2013

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)


Delaware
000-50761
11-3146460
     
(State or Other Jurisdiction of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)

 
14 Plaza Drive, Latham, New York      12110
 
(Address of Principal Executive Offices)                 (Zip Code)
 
 
(518) 798-1215
 
(Registrant’s telephone number, including area code)
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 
 
 

Item 5.07 – Submission of Matters to a Vote of Security Holders.

(a)  
AngioDynamics’ Annual Meeting was held on October 22, 2013.

(b)  
Shareholders voted on the matters set forth below.

1.  
The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2016 Annual Meeting of Shareholders, based upon the following votes:

Nominee
Votes For
Withheld
Broker Non Votes
Jeffrey G. Gold
28,946,733
624,808
2,255,443
Kevin J. Gould
26,487,110
3,102,431
2,255,443
Dennis S. Meteny
26,514,556
3,074,985
2,255,443
 

 
2.  
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2014 was approved based upon the following votes:

 
Votes for approval
31,440,180
 
Votes against
388,835
 
Abstentions
15,969
  There were no broker non-votes for this item.  

 
3.  
The proposal to approve, on an advisory basis, AngioDynamics’ overall executive compensation policies and procedures for its named executive officers was approved based upon the following votes:

 
Votes for approval
28,896,516
 
Votes against
323,401
 
Abstentions
369,624
 
Broker non votes
2,255,443

(c)  
Not applicable.

(d)  
Not applicable.




 
 
 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
ANGIODYNAMICS, INC.
  
   (Registrant)  
       
       
Date: October 25, 2013
By:
/s/  Stephen A. Trowbridge  
    Name:  Stephen A. Trowbridge   
    Title:    Senior Vice President and General Counsel